NHP or drug? How Health Canada actually classifies a peptide

Health Canada sorts every product into one of two separate licensing systems — Natural Health Product (NPN) or drug (DIN) — and one rule decides most peptides before anything else does: an injectable substance is legally barred from ever being a Natural Health Product, full stop, regardless of what's actually in it.

Two licences, two completely different regimes

Health Canada runs two separate licensing systems for anything a person consumes or has administered to them, and they aren't interchangeable versions of the same check. A Natural Health Product (NHP), licensed under the Natural Health Products Regulations (SOR/2003-196), gets an eight-digit Natural Product Number (NPN) after Health Canada reviews it for safety, quality and evidence of the specific health claim made — a lighter evidence bar than a drug, built for products like vitamins, herbal extracts and oral collagen peptides. A drug, authorised under the Food and Drug Regulations, gets a Drug Identification Number (DIN) after the much larger clinical evidence package Health Canada requires for a prescription or over-the-counter medicine. Seeing a number on a label tells you which regime a product went through — it doesn't tell you the two regimes ask the same questions.

The rule that settles it before anything else: how it's administered

Before Health Canada ever gets to evaluating what a peptide does, its own regulations rule out an entire category of products from NHP status on how they're given, not what they contain. Schedule 2 of the Natural Health Products Regulations sets out substances and categories excluded from the definition of a "natural health product" outright, and a substance administered by injection is on that exclusion list — Health Canada's own framing is that an injectable product falls outside the self-care use an NHP licence is meant for. In plain terms: it does not matter whether an injectable peptide is derived from a plant, an animal, or made synthetically, and it does not matter whether a version of the same molecule sold orally would otherwise qualify — the injectable route itself puts a product outside the Natural Health Products Regulations. An injectable peptide can only ever be reviewed as a drug (through a DIN, or an unapproved-and-therefore-illegal product if it hasn't gone through that review) — never as a Natural Health Product, at any dose, from any manufacturer.

Schedule 1: even an oral peptide needs to be on the list

Route of administration is only the first gate. For a peptide sold orally or topically, Health Canada still requires the specific ingredient itself to fall within Schedule 1 of the Natural Health Products Regulations — a defined, closed list of substance categories (plant and algae material, bacteria, fungi and non-human animal material, and their extracts or isolates, among a small number of other categories) that can even be considered for NHP licensing, provided a listed extract or isolate keeps the same primary molecular structure it had before extraction. A synthetic peptide engineered to a specific amino acid sequence for a pharmacological effect — the kind sold as BPC-157, TB-500, or most other "research peptides" — generally doesn't fit Schedule 1's categories at all, oral or not, independent of the parenteral exclusion in section 2 above.

Where this leaves BPC-157 and similar injectable peptides

Put the two gates together and a compound like BPC-157 fails both, in either form: it isn't licensed as a Natural Health Product in any form Health Canada recognises — injectable, oral or topical — and it also isn't authorised as a drug under a DIN. Health Canada's own 9 April 2026 public advisory names BPC-157 by name among unauthorized injectable peptides sold online, and this site's own index of Health Canada enforcement actions documents the companies it has taken public action against for selling products in this same unauthorised category. Neither classification gap is a paperwork oversight waiting to be filed — it's the predictable result of running an injectable, synthetic, purpose-built peptide through a regulatory system built around two other kinds of products entirely.

Why this isn't the same question as the compounding loophole

This site's separate page on Canada's compounding loophole for unapproved peptides covers a real, documented route around the NPN/DIN framework described here: a prescriber can direct a compounding pharmacy to prepare an individualized dose of an ingredient that has never gone through either licensing pathway, under an exemption meant for customized patient care, not as a second door into the market. That mechanism doesn't change anything on this page — BPC-157 still isn't a licensed NHP or an approved drug either way — it's simply a different legal route some clinics have used to supply an ingredient that failed (or never attempted) both of the tests this page describes.

The practical takeaway

An NPN on a bottle of oral collagen peptides means Health Canada reviewed it as a Natural Health Product — a real check, on the more modest evidence standard that regime uses. Nothing sold as an injectable "research peptide" can carry that same number, by definition, no matter how a seller's marketing describes it — the parenteral route alone rules NHP status out. If a seller in Canada implies its injectable product has any form of Health Canada natural-health licensing, that claim is not just unproven — it describes a licence category the product is legally incapable of holding.